Xilio Therapeutics Financials - Benzinga

Xilio Therapeutics Inc

XLONASDAQ

Trade with Public

Trade with Public

$9.17

0.161.78%

At close: Aug 14, 5:00 PM EST

$9.08

-0.09-0.98%

After Hours: Aug 13, 7:39 AM EST

Earnings: Q2 2026 Earnings were released on Wed Aug 12th, before the market open

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Xilio Therapeutics Financials

Xilio Therapeutics (XLO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M Estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 85.27 percent increase over losses of $(2.24) per share

Benzinga Newsdesk

PRO
Xilio Therapeutics Q1 EPS $(0.58) Beats $(0.66) Estimate, Sales $12.648M Beat $8.520M Estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.66) by 12.12 percent. This is a 76.71 percent increase over losses of $(2.49) per share from

Benzinga Newsdesk

PRO
Xilio Therapeutics Q4 EPS $0.81 Beats $(0.12) Estimate, Sales $13.686M Beat $7.960M Estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $(0.12) by 775 percent. This is a 128.93 percent increase over losses of $(2.80) per share from

Benzinga Newsdesk

PRO
Xilio Therapeutics Q3 EPS $(0.11) Misses $(0.03) Estimate, Sales $19.066M Beat $18.635M Estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 50 percent increase over losses of $(0.22) per share from

Benzinga Newsdesk

PRO
Xilio Therapeutics Q2 EPS $(0.16) Misses $(0.08) Estimate, Sales $8.084M Miss $8.210M Estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 33.33 percent increase over losses of $(0.24) per share from

Benzinga Newsdesk

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Avi Kapoor